Ruei‐Min Lu

3.6k total citations · 2 hit papers
18 papers, 2.5k citations indexed

About

Ruei‐Min Lu is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Infectious Diseases. According to data from OpenAlex, Ruei‐Min Lu has authored 18 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Infectious Diseases. Recurrent topics in Ruei‐Min Lu's work include Monoclonal and Polyclonal Antibodies Research (7 papers), SARS-CoV-2 and COVID-19 Research (6 papers) and SARS-CoV-2 detection and testing (4 papers). Ruei‐Min Lu is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), SARS-CoV-2 and COVID-19 Research (6 papers) and SARS-CoV-2 detection and testing (4 papers). Ruei‐Min Lu collaborates with scholars based in Taiwan. Ruei‐Min Lu's co-authors include Han‐Chung Wu, I-Ju Liu, Chi‐Chiu Lee, Hsin‐Jung Li, Chien‐Hsun Wu, Woan‐Yuh Tarn, Minshan Chen, Yu‐Ling Chang, Shih-Han Ko and Kang-Hao Liang and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Biomaterials.

In The Last Decade

Ruei‐Min Lu

17 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of therapeutic antibodies for the treatment of diseases

2020 1.4k citations Ruei‐Min Lu, I-Ju Liu et al. Journal of Biomedical Science profile →
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection

2022 157 citations Ruei‐Min Lu, Shih-Chieh Su et al. Journal of Biomedical Science profile →

Peers

Countries citing papers authored by Ruei‐Min Lu

Since Specialization

Citations

This map shows the geographic impact of Ruei‐Min Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruei‐Min Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruei‐Min Lu more than expected).

Fields of papers citing papers by Ruei‐Min Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruei‐Min Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruei‐Min Lu. The network helps show where Ruei‐Min Lu may publish in the future.

Co-authorship network of co-authors of Ruei‐Min Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Ruei‐Min Lu. A scholar is included among the top collaborators of Ruei‐Min Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruei‐Min Lu. Ruei‐Min Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Technological advancements in antibody-based therapeutics for treatment of diseases 2025 ·Journal of Biomedical Science ·Ruei‐Min Lu, Hsiao-Ling Chiang, (unknown), (unknown), (unknown), (unknown), Kang-Hao Liang, Hung‐Pin Peng, Shih-Han Ko, (unknown), Monika Kumari, Yi‐Jen Su, (unknown), (unknown), Han‐Chung Wu	0
2	Current landscape of mRNA technologies and delivery systems for new modality therapeutics 2024 ·Journal of Biomedical Science ·Ruei‐Min Lu, (unknown), (unknown), Monika Kumari, Guanhong Chen, Ming-Hsiang Hong, (unknown), (unknown), Shih-Han Ko, (unknown), Yi‐Jen Su, (unknown), Wen‐Shan Li, Han‐Chung Wu	34
3	Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice 2023 ·Heliyon ·Ruei‐Min Lu, Kang-Hao Liang, Hsiao-Ling Chiang, Fu‐Fei Hsu, Hsiu-Ting Lin, (unknown), Feng-Yi Ke, Monika Kumari, Yu‐Chi Chou, Mi‐Hua Tao, Yi‐Ling Lin, Han‐Chung Wu	4
4	Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2 2023 ·Journal of Biomedical Science ·Hsiao-Ling Chiang, Kang-Hao Liang, Ruei‐Min Lu, (unknown), Yi‐Ling Lin, Han‐Chung Wu	7
5	A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies 2022 ·Journal of Biomedical Science ·Monika Kumari, Ruei‐Min Lu, Mu‐Chun Li, Jhih‐Liang Huang, Fu‐Fei Hsu, Shih-Han Ko, Feng-Yi Ke, Shih-Chieh Su, Kang-Hao Liang, (unknown), Hsiao-Ling Chiang, Cheng‐Pu Sun, (unknown), Wen‐Shan Li, Hsing‐Pang Hsieh, Mi‐Hua Tao, Han‐Chung Wu	94
6	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection breakdown → 2022 ·Journal of Biomedical Science ·(unknown), Ruei‐Min Lu, Shih-Chieh Su, (unknown), Shih-Han Ko, Feng-Yi Ke, Kang-Hao Liang, (unknown), Han‐Chung Wu	157
7	Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19 2021 ·International Journal of Molecular Sciences ·Ruei‐Min Lu, Shih-Han Ko, Chen Wy, Yu‐Ling Chang, Hsiu-Ting Lin, Han‐Chung Wu	18
8	Antibody cocktail effective against variants of SARS-CoV-2 2021 ·Journal of Biomedical Science ·Kang-Hao Liang, (unknown), Shih-Han Ko, Yu‐Chi Chou, Ruei‐Min Lu, Hsiu-Ting Lin, Chen Wy, Yi‐Ling Lin, Mi‐Hua Tao, Jia‐Tsrong Jan, Han‐Chung Wu	17
9	Imaging and biodistribution of radiolabeled SP90 peptide in BT-483 tumor bearing mice 2020 ·Applied Radiation and Isotopes ·(unknown), (unknown), Liang‐Cheng Chen, (unknown), Serigne Lo, Mingwei Chen, Ruei‐Min Lu, I-Ju Liu, Han‐Chung Wu, Chih-Hsien Chang	2
10	Development of therapeutic antibodies for the treatment of diseases breakdown → 2020 ·Journal of Biomedical Science ·Ruei‐Min Lu, (unknown), I-Ju Liu, Chi‐Chiu Lee, (unknown), Hsin‐Jung Li, Han‐Chung Wu	1397
11	Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer 2019 ·Cancer Science ·Ruei‐Min Lu, (unknown), (unknown), Yu‐Ling Chang, (unknown), Han‐Chung Wu	22
12	Advancement and applications of peptide phage display technology in biomedical science 2016 ·Journal of Biomedical Science ·Chien‐Hsun Wu, I-Ju Liu, Ruei‐Min Lu, Han‐Chung Wu	262
13	Targeted Drug Delivery Systems Mediated by a Novel Peptide in Breast Cancer Therapy and Imaging 2013 ·PLoS ONE ·Ruei‐Min Lu, Minshan Chen, De-Kuan Chang, Chien‐Yu Chiu, (unknown), (unknown), Yi‐Ping Wang, (unknown), (unknown), Albert Lo, Han‐Chung Wu	73
14	Peptide-Mediated Liposomal Doxorubicin Enhances Drug Delivery Efficiency and Therapeutic Efficacy in Animal Models 2013 ·PLoS ONE ·De-Kuan Chang, Pi‐Chun Li, Ruei‐Min Lu, Wann‐Neng Jane, Han‐Chung Wu	37
15	Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery 2011 ·Biomaterials ·Ruei‐Min Lu, Yu‐Ling Chang, Minshan Chen, Han‐Chung Wu	102
16	Epithelial Cell Adhesion Molecule Regulation Is Associated with the Maintenance of the Undifferentiated Phenotype of Human Embryonic Stem Cells 2010 ·Journal of Biological Chemistry ·Tung‐Ying Lu, Ruei‐Min Lu, Mei‐Ying Liao, John Yu, (unknown), Cheng-Fu Kao, Han‐Chung Wu	102
17	The RNA Binding Protein hnRNP Q Modulates the Utilization of Exon 7 in the Survival Motor Neuron 2 (SMN2) Gene 2008 ·Molecular and Cellular Biology ·Hung-Hsi Chen, (unknown), Ruei‐Min Lu, (unknown), Woan‐Yuh Tarn	91
18	The WW Domain-Containing Proteins Interact with the Early Spliceosome and Participate in Pre-mRNA Splicing In Vivo 2004 ·Molecular and Cellular Biology ·Kai‐Ti Lin, Ruei‐Min Lu, Woan‐Yuh Tarn	78

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact